Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Organizing biological data
ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer
Dual targeting CDK4/6 and CDK7 augments tumor response and anti-tumor immunity in breast cancer
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer
ATAC-seq of isolated primary human CD8+ T cells treated with KDACi with polyclonal stimulation for 6 days
RNA-seq of isolated primary human CD8+ T cells treated with KDACi with polyclonal stimulation for 6 days
Gene expression profile at single cell level of iron positive and iron negative cells from subcutaneous implanted syngeneic fibrosarcoma tumors in C57BL/6 mice.
The clinical efficacy of CDK2 inhibition in CDK4/6 inhibitor-resistant HR-positive breast cancer is dependent on p53 but independent of RB
DNA Microarray and Bioinformatic Analysis Reveals the Potential of Whale Oil in Enhancing Hair Growth in C57BL/6 Mice
Dietary n-3/n-6 polyunsaturated fatty acid ratio modulates dry matter intake and inflammation in transition cows through regulating rumen bacteria, liver lipid metabolism and signal transduction
IL-6/gp130 signaling in CD4+ T cells drives the pathogenesis of pulmonary hypertension
RNA-seq analysis of MCF7 xenografts after treatment with OP-1250 and/or CDK4/6 inhibitors palbociclib or ribociclib
Geobacillus stearothermophilus strain:T-6
Geobacillus stearothermophilus strain:T-6 Genome sequencing
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer [RNA-seq_siPRMT5]
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer [pSer2 Pol II ChIP-seq]
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer [RNA-seq_Pemrametostat]
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer [RNA-seq_RBKO vs WT]
Inhibition of GPX4 enhances CDK4/6 inhibitor activity in breast cancer
Loop-extruding Smc5/6 organizes transcription-induced positive DNA supercoils [Hi-C]
Loop-extruding Smc5/6 organizes transcription-induced positive DNA supercoils [RNA-seq]
Loop-extruding Smc5/6 organizes transcription-induced positive DNA supercoils [ChIP-seq]
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on